Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations-Reference-Cited by-同舟云学术

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations

Published:2024-03-14 Issue:6 Volume:67 Page:4346-4375
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Zi-Xuan¹,Li Qing-Qing¹,Cai Jiao¹,Wu Jia-Zhen¹,Wang Jing-Jing¹,Zhang Meng-Yuan¹,Wang Qing-Xin¹,Tong Zhen-Jiang¹,Yang Jin¹,Wei Tian-Hua¹,Zhou Yun¹,Dai Wei-Chen¹,Ding Ning¹,Leng Xue-Jiao¹,Sun Shan-Liang¹,Xue Xin¹^ORCID,Yu Yan-Cheng¹^ORCID,Yang Ye²,Li Nian-Guang¹^ORCID,Shi Zhi-Hao³

Affiliation:

1. National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China

2. School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China

3. Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, China

Funder

Nanjing University of Chinese Medicine

National Key Research and Development Program of China

Natural Science Foundation of Jiangsu Province

National Natural Science Foundation of China

National Administration of Traditional Chinese Medicine

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02319

Reference169 articles.

1. The importance of the RET gene in thyroid cancer and therapeutic implications

2. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas

3. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023);Journal of Medicinal Chemistry;2024-07-12

2. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives;International Journal of Molecular Sciences;2024-05-17